Gu Jianchun, Zheng Leizhen, Zhang Li, Chen Siyu, Zhu Meiling, Li Xiaoping, Wang Yajie
Department of Oncology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200092, China.
Tumour Biol. 2015 Apr;36(4):3001-7. doi: 10.1007/s13277-014-2933-6. Epub 2014 Dec 17.
The molecular biomarkers human epidermal growth factor receptor-2 (HER2) and trefoil factor 3 (TFF3) are reported to play important roles in the pathogenesis of gastric cancer (GC). In this study, we investigated the clinicopathological and prognostic significance of TFF3 and HER2 expression in GC and explored the correlation between these two biomarkers. Ninety-two patients who were diagnosed with GC were enrolled. TFF3 and HER2 expression was determined on tumor tissues. The results showed that TFF3 and HER2 were positively expressed in 42.7 and 10.9% of the cases, respectively. There were significantly higher rates of TFF3 positivity in patients with deep invasive tumors and advanced stage ones. Patients with negative TFF3 staining survived longer than those with the presence of TFF3, with 5-year overall survival (OS) rates of 57.1 ± 7.1 and 39.5 ± 7.5%, respectively (P = 0.033). However, HER2 positivity was not significantly associated with OS (P = 0.262). Multivariate analysis demonstrated TFF3 expression to be an independent indicator for short-term survival, with a hazard ratio of 2.327 (95% confidence interval (CI), 1.202-4.507, P = 0.012). There was a trend that the expression of TFF3 was more frequent in HER2 negative tumors than in HER2 positive ones (positive rates: 16.3 vs. 4.7%, P = 0.098). Patients with HER2-negative/TFF3-negative GC presented higher OS than those with other phenotypes (P = 0.009). This study suggests that TFF3 is an independent indicator for survival in GC, while HER2 is not associated with the outcome. Patients with HER2-negative/TFF3-negative GC have the best outcome.
分子生物标志物人表皮生长因子受体2（HER2）和三叶因子3（TFF3）据报道在胃癌（GC）的发病机制中起重要作用。在本研究中，我们调查了TFF3和HER2在GC中的表达的临床病理及预后意义，并探讨了这两种生物标志物之间的相关性。纳入了92例被诊断为GC的患者。在肿瘤组织上测定TFF3和HER2的表达。结果显示，TFF3和HER2分别在42.7%和10.9%的病例中呈阳性表达。在肿瘤浸润深和晚期的患者中，TFF3阳性率显著更高。TFF3染色阴性的患者比TFF3阳性的患者存活时间更长，5年总生存率（OS）分别为57.1±7.1%和39.5±7.5%（P = 0.033）。然而，HER2阳性与OS无显著相关性（P = 0.262）。多变量分析表明TFF3表达是短期生存的独立指标，风险比为2.327（95%置信区间（CI），1.202 - 4.507，P = 0.012）。有一种趋势是，TFF3在HER2阴性肿瘤中的表达比在HER2阳性肿瘤中更频繁（阳性率：16.3%对4.7%，P = 0.098）。HER2阴性/TFF3阴性的GC患者的OS高于其他表型的患者（P = 0.009）。本研究表明，TFF3是GC生存的独立指标，而HER2与预后无关。HER2阴性/TFF3阴性的GC患者预后最佳。
